Memoquin

Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC₅₀ values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD)^[1][2]. In Vitro:Memoquin inhibits hAChE, Aβ(1-40) aggregation induced by hAChE, Aβ(1-42) self-aggregation and BACE-1 with IC₅₀ values of 0.00155, 28.3, 5.93 and 0.108 μM, respectively^[2].
Memoquin shows binding properties to hAChE with a K_i value of 2.6 nM^[2]. In Vivo:Memoquin (7-15 mg/kg; oral administration, once) rescues memory deficits of scopolamine-induced amnesia models^[1].
Memoquin (15 mg/kg; oral administration, once daily, for 2-6 days) fully rescues memory deficits of Aβ_1-42-induced amnesia models with a 6 days treatment^[1].